Issue Date: January 10, 2011
BASF Takes A Partner In Medical Polymers
BASF’s Future Business subsidiary has signed an agreement with Interface Biologics to develop plastics for medical devices. The two firms plan polymer formulations that combine Interface’s blood-clot-preventing additives with BASF’s antimicrobial technology. Interface’s additives are low-molecular-weight fluorooligomers that are under development for use in catheters and kidney dialysis equipment because of their ability to reduce blood platelet adhesion. The firm was spun off from the University of Toronto in 2001.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society